Latigo Biotherapeutics, Inc. (LTGO) income statement
LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.31−0.45 (-3.27%)
Close on Nov 18, 2026Market cap $882.44MP/E –Yield 0.00%
Latigo Biotherapeutics, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 29.11
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 2873.4%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.24
- Dividend yield
- 0.00%
See a number that looks wrong?